Key Highlights
● JPMorgan initiated Praxis coverage with an Overweight rating and a $700 price target.
● No closing move for Praxis shares was reported on Friday.
● Praxis develops treatments for central nervous system disorders such as epilepsy and movement disorders.
● Clinical-stage biotech names fell in a rate-driven selloff as large health care held up.
A bullish start from JPMorgan
Praxis Precision Medicines (NASDAQ:PRAX) was in focus on Friday after JPMorgan initiated coverage with an Overweight rating and a $700 price target, according to analyst-call roundups.
The details of JPMorgan's investment case were not included in the available summaries, and no closing move for Praxis shares was reported. The initiation nonetheless put the company on the radar of investors on a day when much of the market was retreating.
Praxis is a clinical-stage drug company that develops treatments for disorders of the central nervous system, with a focus on conditions such as epilepsy and movement disorders. Its approach centers on using genetic insights to target imbalances in brain signaling. Like many drug developers, its valuation depends heavily on clinical trial results and the path to regulatory approval.
A busy day for analyst initiations
JPMorgan's move was one of several notable initiations and reinstatements on Friday. Truist reinstated coverage of Alkermes (NASDAQ:ALKS), another neuroscience-focused drugmaker, at Buy with a $55 target. Macquarie launched coverage of six aerospace and defense names, including AeroVironment (NASDAQ:AVAV), Kratos (NASDAQ:KTOS) and Karman (NYSE:KRMN), all at Outperform. Needham initiated a group of retailers, rating Victoria's Secret (NYSE:VSCO), Urban Outfitters (NASDAQ:URBN) and Boot Barn (NYSE:BOOT) at Buy. CIBC started Constellation Energy (NASDAQ:CEG) at Outperform with a $358 target, and StoneX began Toll Brothers (NYSE:TOL) at Buy with a $165 target.
There were notable downgrades as well. KeyBanc cut Workday (NASDAQ:WDAY), Goldman Sachs moved Klaviyo (NYSE:KVYO) to Neutral, and a string of brokers downgraded Varonis (NASDAQ:VRNS) after it agreed to be acquired by Proofpoint.
Biotech under pressure from rates
The initiation landed in a tough tape for smaller drug developers. Market commentary described a rate-driven selloff in long-duration and clinical-stage health care names on Friday. Novavax (NASDAQ:NVAX) plunged, PacBio (NASDAQ:PACB) sank, and Ocular Therapeutix (NASDAQ:OCUL), QuidelOrtho (NASDAQ:QDEL), Azenta (NASDAQ:AZTA) and Repligen (NASDAQ:RGEN) all fell. Moderna (NASDAQ:MRNA) tumbled as investors trimmed positions ahead of Phase 3 data with Merck (NYSE:MRK) later this month, market reports said.
The 10-year Treasury yield eased to roughly 5.1 on Friday, according to market data, but it touched its highest level since 2002 earlier in October. Elevated yields reduce the present value of profits that may be years away, which is why clinical-stage companies are often sensitive to rate moves.
Large health care companies were a different story. Market reports showed that the health care sector fund hit records as investors rotated into defensive areas of the market.
The broader market
The Nasdaq Composite fell 572.99 points to 26,140.03 on Friday, capping its worst week since June as chip, software and AI infrastructure stocks sold off. The S&P 500 lost 84.62 points to 7,659.44, and the Dow Jones Industrial Average slipped 175.28 points to 52,002.41. The Cboe Volatility Index rose 3.53 points to 19.99.
The central theme, according to market commentary, was a shift in focus from what artificial intelligence can do to how its build-out will be financed. Energy, utilities and consumer staples gained as money moved out of technology.
Praxis Readouts and Broker Follow-Ups
The macro calendar matters too. The Federal Reserve's next decision is due on Oct 28, and the PCE inflation report follows on Oct 29. Fed Chair Kevin Warsh declined to signal his intentions, saying: "I don't prejudge meetings." The direction of Treasury yields after those events will help determine whether biotech stocks on the Nasdaq Composite can find their footing.
For Praxis, the next catalysts are likely to come from its clinical programs, including trial readouts and any regulatory updates, which typically drive the largest moves in clinical-stage biotech stocks. Investors will be watching whether other brokers follow JPMorgan's lead.






Please wait processing your request...